• Please log in or register to access this feature.

Correspondence

You have free access to this content

Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura

  1. John Chapin1,
  2. Babette Weksler1,
  3. Cynthia Magro2,
  4. Jeffrey Laurence1

Article first published online: 13 MAR 2012

DOI: 10.1111/j.1365-2141.2012.09084.x

Issue

British Journal of Haematology

British Journal of Haematology

Volume 157, Issue 6, pages 772–774, June 2012

Additional Information

How to Cite

Chapin, J., Weksler, B., Magro, C. and Laurence, J. (2012), Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. British Journal of Haematology, 157: 772–774. doi: 10.1111/j.1365-2141.2012.09084.x

Author Information

  1. 1

    Division of Hematology-Oncology, New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY, USA

  2. 2

    Department of Pathology, New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY, USA

*joc9160@nyp.org

Publication History

  1. Issue published online: 25 MAY 2012
  2. Article first published online: 13 MAR 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (172K)

References

  • Chen, J., Reheman, A., Gushiken, F.C., Nolasco, L., Fu, X., Moake, J.L., Ni, H. & López, J.A. (2011) N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. Journal of Clinical Investigations, 121, 593–603.
  • Dragon-Durey, M.A. & Fremeaux-Bacchi, V. (2005) Atypical haemolytic uraemic syndrome mutations in complement regulator genes. Springer Seminars in Immunopathology, 27, 359–374.
  • Mache, C.J., Acham-Roschitz, B., Fremeaux-Bacchi, V., Kirschfink, M., Zipfel, P.F., Roedl, S., Vester, U. & Ring, E. (2009) Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clinical Journal of the American Society of Nephrology, 4, 1312–1316.
  • Mitra, D., Jaffe, E.A., Weksler, B., Hajjar, K.A., Soderland, C. & Laurence, J. (1997) Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood, 89, 1224–1234.
  • Noris, M., Bucchioni, S., Galbusera, M., Donadelli, R., Bresin, E., Castelletti, F., Caprioli, J., Brioschi, S., Scheiflinger, F. & Remuzzi, G. (2005) Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. Journal of the American Society of Nephrology, 16, 1177–1183.
  • Raife, T.J. (2005) The changing paradigm of thrombotic thrombocytopenic purpura. Seminars in Thrombosis and Hemostasis, 31, 641–651.
  • Roumenina, L., Loirat, C., Dragon-Durey, M.A., Halbwachs-Mecarelli, L., Sautes-Fridman, C. & Fremeaux-Bacchi, V. (2011) Alternative complement pathway assessment in patients with atypical HUS. Journal of Immunology Methods, 365, 8–26.
  • Ruiz-Torres, M.P., Casiraghi, F., Galbusera, M., Macconi, D., Gastoldi, S., Todeschini, M., Porrati, F., Belotti, D., Pogliani, E.M., Noris, M. & Remuzzi, G. (2005) Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thrombosis and Haemostasis, 93, 443–452.
  • Sanchez-Corral, P. & Melgosa, M. (2010) Advances in understanding the aetiology of atypical Haemolytic Uraemic Syndrome. British Journal of Haematology, 150, 529–542.
    Direct Link:
  • Waters, A. & Licht, C. (2011) aHUS caused by complement dysregulation: new therapies on the horizon. Pediatric Nephrology, 26, 41–57.
View Full Article (HTML) Get PDF (172K)